22nd Jul 2021 15:16
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 21 July 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 2,166,566 3.26 | 134,212 0.20 | ||||
(2) Derivatives (other than options) | 124,887 0.19 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 2,291,453 3.45 | 134,212 0.20 | ||||
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Sale(Borrow Return)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales | 45,000
4 4,247 4 16 201 4 9 166 22 5 6 7 33 3 2
135 165 216 1,100 227 4,247 681 1,750 | N/A
3.5200 USD 3.5538 USD 3.5575 USD 3.5600 USD 3.5668 USD 3.5800 USD 3.5867 USD 3.6184 USD 3.6205 USD 3.6240 USD 3.6250 USD 3.6300 USD 3.6400 USD 3.6500 USD 3.6600 USD
3.5200 USD 3.5261 USD 3.5313 USD 3.5355 USD 3.5400 USD 3.5538 USD 3.5581 USD 3.5975 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Short | 4,247 | 3.5538 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any
other person relating to the voting rights of any relevant securities under any option referred to on this form
or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 22 July 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma